Ilios Therapeutics is a Harvard spin-off with the goal of developing innovative therapies for neurodegenerative diseases such as ALS, Alzheimer’s and Parkinson’s. The company synthesizes first-in-class small molecules, using validated therapeutic agents of natural origin, into a single drug capable of synergistically targeting multiple complementary mechanisms that are at the root of neuronal death.
Currently, drugs for neurodegenerative diseases show low efficacy, have several side effects and are only able to hit one target. Ilios Therapeutics’ innovative and synergistic approach allows it to focus on three complementary targets, hitting the different causes of the disease with a single drug.
Founded in 2022 by Luca Giani (CEO) and Fares Nigim, the team, supported by a high-profile advisory board, has so far worked on the chemical side to study compound synthesis. With the investment, the company is ready to start biological tests on cellular and animal models.
Location: United States, Massachusetts, Cambridge
Employees: 1-10